{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:20:52Z","timestamp":1792113652591,"version":"4.4.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0B2519N"],"award-info":[{"award-number":["G0B2519N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["SB\/1S23819N"],"award-info":[{"award-number":["SB\/1S23819N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S59621N"],"award-info":[{"award-number":["1S59621N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stichting Alzheimer Onderzoek"},{"name":"University of London Chadburn Academic Clinical Lectureship in Medicine"},{"DOI":"10.13039\/501100000320","name":"Alzheimer&apos;s Society","doi-asserted-by":"publisher","award":["AS-CTF-18-001"],"award-info":[{"award-number":["AS-CTF-18-001"]}],"id":[{"id":"10.13039\/501100000320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002283","name":"Alzheimer&apos;s Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UK Dementia Research Institute and the NIHR UCLH Biomedical Research Centre"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Familial Alzheimer\u2019s disease (FAD), caused by mutations in Presenilin\n                    <jats:italic>(PSEN1\/2)<\/jats:italic>\n                    and Amyloid Precursor Protein\n                    <jats:italic>(APP<\/jats:italic>\n                    ) genes, is associated with an early age at onset (AAO) of symptoms. AAO is relatively consistent within families and between carriers of the same mutations, but differs markedly between individuals carrying different mutations. Gaining a mechanistic understanding of why certain mutations manifest several decades earlier than others is extremely important in elucidating the foundations of pathogenesis and AAO. Pathogenic mutations affect the protease (PSEN\/\u03b3-secretase) and the substrate (APP) that generate amyloid \u03b2 (A\u03b2) peptides. Altered A\u03b2 metabolism has long been associated with AD pathogenesis, with absolute or relative increases in A\u03b242 levels most commonly implicated in the disease development. However, analyses addressing the relationships between these A\u03b242 increments and AAO are inconsistent. Here, we investigated this central aspect of AD pathophysiology via comprehensive analysis of 25 FAD-linked A\u03b2 profiles. Hypothesis- and data-driven approaches demonstrate linear correlations between mutation-driven alterations in A\u03b2 profiles and AAO. In addition, our studies show that the A\u03b2 (37\u2009+\u200938\u2009+\u200940)\u2009\/\u2009(42\u2009+\u200943) ratio offers predictive value in the assessment of \u2018unclear\u2019\n                    <jats:italic>PSEN1<\/jats:italic>\n                    variants. Of note, the analysis of PSEN1 variants presenting additionally with spastic paraparesis, indicates that a different mechanism underlies the aetiology of this distinct clinical phenotype. This study thus delivers valuable assays for fundamental, clinical and genetic research as well as supports therapeutic interventions aimed at shifting A\u03b2 profiles towards shorter A\u03b2 peptides.\n                  <\/jats:p>","DOI":"10.1038\/s41380-022-01518-6","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T10:26:56Z","timestamp":1648808816000},"page":"2821-2832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["A\u03b2 profiles generated by Alzheimer\u2019s disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5721-8041","authenticated-orcid":false,"given":"Dieter","family":"Petit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7479-0768","authenticated-orcid":false,"given":"Sara Guti\u00e9rrez","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5853-3465","authenticated-orcid":false,"given":"Katarzyna Marta","family":"Zoltowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1789-4090","authenticated-orcid":false,"given":"Thomas","family":"Enzlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4467-128X","authenticated-orcid":false,"given":"Antoinette","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Szaruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick C.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8239-559X","authenticated-orcid":false,"given":"Luc\u00eda","family":"Ch\u00e1vez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"1518_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper B, Karran E. The cellular phase of Alzheimer\u2019s disease. Cell. 2016;164:603\u201315.","journal-title":"Cell"},{"key":"1518_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8:1\u201314.","journal-title":"EMBO Mol Med"},{"key":"1518_CR3","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/S1474-4422(16)30193-4","volume":"15","author":"NS Ryan","year":"2016","unstructured":"Ryan NS, Nicholas JM, Weston PSJ, Liang Y, Lashley T, Guerreiro R, et al. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer\u2019s disease: a case series. Lancet Neurol. 2016;15:1326\u201335.","journal-title":"Lancet Neurol"},{"key":"1518_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/34910","volume":"391","author":"B De Strooper","year":"1998","unstructured":"De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature.1998;391:387\u201390.","journal-title":"Nature"},{"key":"1518_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/19077","volume":"398","author":"MS Wolfe","year":"1999","unstructured":"Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature.1999;398:513\u20137.","journal-title":"Nature"},{"key":"1518_CR6","doi-asserted-by":"publisher","first-page":"28669","DOI":"10.1074\/jbc.274.40.28669","volume":"274","author":"H Steiner","year":"1999","unstructured":"Steiner H, Duff K, Capell A, Romig H, Grim MG, Lincoln S, et al. A loss of function mutation of presenilin-2 interferes with amyloid \u03b2 -peptide production and notch signaling. J Biol Chem. 1999;274:28669\u201373.","journal-title":"J Biol Chem"},{"key":"1518_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/35024009","volume":"407","author":"G Yu","year":"2000","unstructured":"Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, et al. Nicastrin modulates presenilin-mediated notch\/glp-1 signal transduction and betaAPP processing. Nature.2000;407:48\u201354.","journal-title":"Nature"},{"key":"1518_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1534-5807(02)00189-2","volume":"3","author":"R Francis","year":"2002","unstructured":"Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, et al. aph-1 and pen-2 are required for Notch pathway signaling, \u03b3-secretase cleavage of \u03b2APP, and presenilin protein accumulation. Dev Cell. 2002;3:85\u201397.","journal-title":"Dev Cell"},{"key":"1518_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1073\/pnas.022523499","volume":"99","author":"C Goutte","year":"2002","unstructured":"Goutte C, Tsunozaki M, Hale VA, Priess JR. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci USA. 2002;99:775\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1518_CR10","doi-asserted-by":"publisher","first-page":"13042","DOI":"10.1523\/JNEUROSCI.2362-09.2009","volume":"29","author":"M Takami","year":"2009","unstructured":"Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, et al. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci. 2009;29:13042\u201352.","journal-title":"J Neurosci"},{"key":"1518_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/383710a0","volume":"383","author":"K Duff","year":"1996","unstructured":"Duff K, Eckmant C, Zehr C, Yu X, Cristian-Mihail P, Perez-tur J, et al. Increased amyloid-A\u03b242(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710\u20133.","journal-title":"Nature"},{"key":"1518_CR12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0896-6273(00)80230-5","volume":"17","author":"DR Borchelt","year":"1996","unstructured":"Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al. Familial Alzheimer\u2019s disease\u2013linked presenilin 1 variants elevate A\u03b2 1\u201342\/1\u201340 ratio in vitro and in vivo. Neuron.1996;17:1005\u201313.","journal-title":"Neuron"},{"key":"1518_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid \u03b2 protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat Med. 1996;2:925\u20138.","journal-title":"Nat Med"},{"key":"1518_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ana.410400205","volume":"40","author":"DMA Mann","year":"1996","unstructured":"Mann DMA, Iwatsubo T, Cairns TNJ, Lantos PL, Nochlin D, Prihar G, et al. Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer\u2019 s Disease: Predominance of Abeta42(43). Am Neurol Assoc. 1996;40:149\u201356.","journal-title":"Am Neurol Assoc"},{"key":"1518_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nm0197-67","volume":"3","author":"M Citron","year":"1997","unstructured":"Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, et al. Mutant presenilins of Alzheimer\u2019s disease increase production of 42-residue amyloid \u03b2-protein in both transfected cells and transgenic mice. Nat Med. 1997;3:67\u201372.","journal-title":"Nat Med"},{"key":"1518_CR16","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1073\/pnas.94.5.2025","volume":"94","author":"T Tomita","year":"1997","unstructured":"Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA. 1997;94:2025\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1518_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0304-3940(99)00187-1","volume":"265","author":"O Murayama","year":"1999","unstructured":"Murayama O, Tomita T, Nihonmatsu N, Murayama M, Sun X, Honda T, et al. Enhancement of amyloid \u03b2 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer\u2019s disease. Neurosci Lett. 1999;265:61\u20133.","journal-title":"Neurosci Lett"},{"key":"1518_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/humu.20336","volume":"27","author":"S Kumar-singh","year":"2006","unstructured":"Kumar-singh S, Theuns J, Van BroeckB, Pirici D, Vennekens K, Corsmit E, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased A\u03b242 and decreased A\u03b240. Hum Mutat. 2006;27:686\u201395.","journal-title":"Hum Mutat"},{"key":"1518_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.neuron.2015.02.010","volume":"85","author":"D Xia","year":"2015","unstructured":"Xia D, Watanabe H, Wu B, Lee SH, Li Y, Tsvetkov E, et al. Presenilin-1 knockin mice reveal loss-of-function mechanism for familial alzheimer\u2019s disease. Neuron. 2015;85:967\u201381.","journal-title":"Neuron"},{"key":"1518_CR20","doi-asserted-by":"publisher","first-page":"104817","DOI":"10.1016\/j.nbd.2020.104817","volume":"139","author":"S Hsu","year":"2020","unstructured":"Hsu S, Pimenova AA, Hayes K, Villa JA, Rosene MJ, Jere M, et al. Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2. Neurobiol Dis. 2020;139:104817.","journal-title":"Neurobiol Dis"},{"key":"1518_CR21","doi-asserted-by":"publisher","first-page":"189ra77","DOI":"10.1126\/scitranslmed.3005615","volume":"5","author":"R Potter","year":"2013","unstructured":"Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, et al. Increased in vivo amyloid- 42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5:189ra77.","journal-title":"Sci Transl Med"},{"key":"1518_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/ana.410430217","volume":"43","author":"ND Mehta","year":"1998","unstructured":"Mehta ND, Refolo LM, Eckman C, Sanders S, Yager D, Perez-Tur J, et al. Increased A\u03b242(43) from cell lines expressing presenilin 1 mutations. Ann Neurol. 1998;43:256\u20138.","journal-title":"Ann Neurol"},{"key":"1518_CR23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neurobiolaging.2004.08.002","volume":"26","author":"M Duering","year":"2005","unstructured":"Duering M, Grimm MOW, Grimm HS, Schr J, Hartmann T. Mean age of onset in familial Alzheimer\u2019s disease is determined by amyloid beta 42. Neurobiol Aging. 2005;26:785\u20138.","journal-title":"Neurobiol Aging"},{"key":"1518_CR24","doi-asserted-by":"publisher","first-page":"E476","DOI":"10.1073\/pnas.1618657114","volume":"114","author":"L Sun","year":"2017","unstructured":"Sun L, Zhou R, Yang G, Shi Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A\u03b242 and A\u03b240 peptides by \u03b3-secretase. Proc Natl Acad Sci USA. 2017;114:E476\u201385.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1518_CR25","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1038\/emboj.2012.79","volume":"31","author":"L Ch\u00e1vez-Guti\u00e9rrez","year":"2012","unstructured":"Ch\u00e1vez-Guti\u00e9rrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, et al. The mechanism of \u03b3-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31:2261\u201374.","journal-title":"EMBO J"},{"key":"1518_CR26","doi-asserted-by":"publisher","first-page":"31043","DOI":"10.1074\/jbc.M114.581165","volume":"289","author":"MA Fernandez","year":"2014","unstructured":"Fernandez MA, Klutkowski JA, Freret T, Wolfe MS. Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid \u03b2-peptides (A\u03b2) by \u03b3-secretase to increase 42-to-40-residue A\u03b2. J Biol Chem. 2014;289:31043\u201352.","journal-title":"J Biol Chem"},{"key":"1518_CR27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.neuron.2016.03.010","volume":"90","author":"S Veugelen","year":"2016","unstructured":"Veugelen S, Saito T, Saido TCTC, Ch\u00e1vez-Guti\u00e9rrez L, De Strooper B, Ch\u00e1vez-Gutierrez L, et al. Familial Alzheimer\u2019s disease mutations in presenilin generate amyloidogenic A\u03b2 peptide seeds. Neuron.2016;90:410\u20136.","journal-title":"Neuron"},{"key":"1518_CR28","doi-asserted-by":"publisher","first-page":"458","DOI":"10.15252\/emmm.201505952","volume":"8","author":"B Kretner","year":"2016","unstructured":"Kretner B, Trambauer J, Fukumori A, Mielke J, Kuhn P, Kremmer E, et al. Generation and deposition of A\u03b243 by the virtually inactive presenilin\u20101 L435F mutant contradicts the presenilin loss\u2010of\u2010function hypothesis of Alzheimer\u2019s disease. EMBO Mol Med. 2016;8:458\u201365.","journal-title":"EMBO Mol Med"},{"key":"1518_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cell.2017.07.004","volume":"170","author":"M Szaruga","year":"2017","unstructured":"Szaruga M, Munteanu B, Lismont S, Veugelen S, Horr\u00e9 K, Mercken M, et al. Alzheimer\u2019s-causing mutations shift A\u03b2 length by destabilizing \u03b3-secretase-A\u03b2n interactions. Cell. 2017;170:443\u201356.e14.","journal-title":"Cell"},{"key":"1518_CR30","doi-asserted-by":"publisher","first-page":"100281","DOI":"10.1016\/j.jbc.2021.100281","volume":"296","author":"S Devkota","year":"2021","unstructured":"Devkota S, Williams TD, Wolfe MS. Familial Alzheimer s disease mutations in amyloid protein precursor alter proteolysis by \u03b3-secretase to increase amyloid \u03b2-peptides of \u226545 residues. J Biol Chem. 2021;296:100281.","journal-title":"J Biol Chem"},{"key":"1518_CR31","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1093\/brain\/awab166","volume":"144","author":"A O\u2019Connor","year":"2021","unstructured":"O\u2019Connor A, Pannee J, Poole T, Arber C, Portelius E, Swift IJ, et al. Plasma amyloid-\u03b2 ratios in autosomal dominant Alzheimer\u2019s disease: the influence of genotype. Brain. 2021;144:2964\u201370.","journal-title":"Brain"},{"key":"1518_CR32","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1523\/JNEUROSCI.1575-04.2005","volume":"25","author":"Y Qi-Takahara","year":"2005","unstructured":"Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, et al. Longer forms of amyloid-\u03b2 protein: implications for the mechanism of intramembrane cleavage by \u03b3-secretase. J Neurosci. 2005;25:436\u201345.","journal-title":"J Neurosci"},{"key":"1518_CR33","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1074\/jbc.M707103200","volume":"283","author":"S Yagishita","year":"2008","unstructured":"Yagishita S, Morishima-Kawashima M, Ishiura S, Ihara Y. A\u03b246 is processed to A\u03b240 and A\u03b243, but not to A\u03b242, in the low density membrane domains. J Biol Chem. 2008;283:733\u20138.","journal-title":"J Biol Chem"},{"key":"1518_CR34","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1038\/ncomms3246","volume":"4","author":"M Dimitrov","year":"2013","unstructured":"Dimitrov M, Alattia JR, Lemmin T, Lehal R, Fligier A, Houacine J, et al. Alzheimer\u2019s disease mutations in APP but not \u03b3-secretase modulators affect epsilon-cleavage-dependent AICD production. Nat Commun. 2013;4:2246.","journal-title":"Nat Commun"},{"key":"1518_CR35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41598-019-56343-9","volume":"10","author":"YE Kim","year":"2020","unstructured":"Kim YE, Cho H, Kim HJ, Na DL, Seo SW, Ki CS. PSEN1 variants in Korean patients with clinically suspicious early-onset familial Alzheimer\u2019s disease. Sci Rep. 2020;10:4\u201310.","journal-title":"Sci Rep"},{"key":"1518_CR36","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/humu.9458","volume":"27","author":"C Dumanchin","year":"2006","unstructured":"Dumanchin C, Tournier I, Martin C, Didic M, Belliard S, Carlander B, et al. Biological effects of four PSEN1 gene mutations causing Alzheimer disease with spastic paraparesis and cotton wool plaques. Hum Mutat. 2006;27:1063.","journal-title":"Hum Mutat"},{"key":"1518_CR37","first-page":"e12186","volume":"13","author":"V Chelban","year":"2021","unstructured":"Chelban V, Breza M, Szaruga M, Vandrovcova J, Murphy D, Lee C, et al. Spastic paraplegia preceding PSEN1 \u2010related familial Alzheimer\u2019s disease. Alzheimer\u2019s Dement Diagnosis. Assess Dis Monit. 2021;13:e12186.","journal-title":"Assess Dis Monit"},{"key":"1518_CR38","doi-asserted-by":"publisher","first-page":"e101494","DOI":"10.15252\/embj.2019101494","volume":"38","author":"D Petit","year":"2019","unstructured":"Petit D, Hitzenberger M, Lismont S, Zoltowska KM, Ryan NS, Mercken M, et al. Extracellular interface between APP and Nicastrin regulates A\u03b2 length and response to \u03b3\u2010secretase modulators. EMBO J. 2019;38:e101494.","journal-title":"EMBO J"},{"key":"1518_CR39","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/mp.2015.177","volume":"21","author":"JI V\u00e9lez","year":"2016","unstructured":"V\u00e9lez JI, Lopera F, Patel HR, Johar AS, Chuah A, Tob\u00f3n C, et al. APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer\u2019s disease. Mol Psychiatry. 2016;21:916\u201324.","journal-title":"Mol Psychiatry"},{"key":"1518_CR40","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1074\/jbc.M113.530907","volume":"289","author":"H Acx","year":"2014","unstructured":"Acx H, Ch\u00e1vez-Guti\u00e9rrez L, Serneels L, Lismont S, Benurwar M, Elad N, et al. Signature amyloid beta profiles are produced by different gamma-secretase complexes. J Biol Chem. 2014;289:4346\u201355.","journal-title":"J Biol Chem"},{"key":"1518_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.cell.2016.05.020","volume":"166","author":"R Sannerud","year":"2016","unstructured":"Sannerud R, Esselens C, Ejsmont P, Mattera R, Rochin L, Tharkeshwar AK, et al. Restricted location of PSEN2\/\u03b3-secretase determines substrate specificity and generates an intracellular A\u03b2 pool. Cell. 2016;166:193\u2013208.","journal-title":"Cell"},{"key":"1518_CR42","doi-asserted-by":"publisher","first-page":"17297","DOI":"10.1523\/JNEUROSCI.1451-12.2012","volume":"32","author":"T Borgeg\u00e5rd","year":"2012","unstructured":"Borgeg\u00e5rd T, Gustavsson S, Nilsson C, Parpal S, Klintenberg R, Berg A-L, et al. Alzheimer\u2019s disease: presenilin 2-sparing \u03b3-secretase inhibition is a tolerable A\u03b2 peptide-lowering strategy. J Neurosci. 2012;32:17297\u2013305.","journal-title":"J Neurosci"},{"key":"1518_CR43","doi-asserted-by":"publisher","first-page":"11872","DOI":"10.1073\/pnas.96.21.11872","volume":"96","author":"A Herreman","year":"1999","unstructured":"Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci USA. 1999;96:11872\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1518_CR44","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1084\/jem.20150892","volume":"212","author":"M Szaruga","year":"2015","unstructured":"Szaruga M, Veugelen S, Benurwar M, Lismont S, Sepulveda-Falla D, Lleo A, et al. Qualitative changes in human \u03b3-secretase underlie familial Alzheimer\u2019s disease. J Exp Med. 2015;212:2003\u201313.","journal-title":"J Exp Med"},{"key":"1518_CR45","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1471-4159.2004.02858.x","volume":"92","author":"ES Walker","year":"2005","unstructured":"Walker ES, Martinez M, Brunkan AL, Goate A. Presenilin 2 familial Alzheimer\u2019 s disease mutations result in partial loss of function and dramatic changes in A\u03b242\/40 ratios. J Neurochem. 2005;92:294\u2013301.","journal-title":"J Neurochem"},{"key":"1518_CR46","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/hmg\/10.16.1665","volume":"10","author":"C De Jonghe","year":"2001","unstructured":"De Jonghe C, Esselens C, Kumar-singh S, Craessaerts K, Serneels S, Checler F, et al. Pathogenic APP mutations near the \u03b3-secretase cleavage site differentially affect A\u03b2 secretion and APP C-terminal fragment stability. Hum Mol Genet. 2001;10:1665\u201371.","journal-title":"Hum Mol Genet"},{"key":"1518_CR47","doi-asserted-by":"publisher","first-page":"15425","DOI":"10.1021\/jacs.6b08742","volume":"138","author":"S Lee","year":"2016","unstructured":"Lee S, Mao A, Bhattacharya S, Robertson N, Grisshammer R, Tate CG, et al. How do short chain nonionic detergents destabilize G-protein-coupled receptors? J Am Chem Soc. 2016;138:15425\u201333.","journal-title":"J Am Chem Soc"},{"key":"1518_CR48","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3233\/JAD-180829","volume":"66","author":"N Tang","year":"2018","unstructured":"Tang N, Kepp KP. A\u03b242\/A\u03b240 ratios of presenilin 1 mutations correlate with clinical onset of Alzheimer\u2019s Disease. J Alzheimer\u2019s Dis. 2018;66:939\u201345.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1518_CR49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10048-006-0053-1","volume":"7","author":"J Murrell","year":"2006","unstructured":"Murrell J, Ghetti B, Cochran E, Macias-Islas MA, Medina L, Varpetian A, et al. The A431E mutation in PSEN1 causing Familial Alzheimer\u2019s Disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics 2006;7:277\u20139.","journal-title":"Neurogenetics"},{"key":"1518_CR50","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ajmg.10250","volume":"114","author":"M Matsubara-Tsutsui","year":"2002","unstructured":"Matsubara-Tsutsui M, Yasuda M, Yamagata H, Nomura T, Taguchi K, Kohara K, et al. Molecular evidence of presenilin 1 mutation in familial early onset dementia. Am J Med Genet. 2002;114:292\u20138.","journal-title":"Am J Med Genet"},{"key":"1518_CR51","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41380-019-0410-8","volume":"25","author":"C Arber","year":"2020","unstructured":"Arber C, Toombs J, Lovejoy C, Ryan NS, Paterson RW, Willumsen N, et al. Familial Alzheimer\u2019s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Mol Psychiatry. 2020;25:2919\u201331.","journal-title":"Mol Psychiatry"},{"key":"1518_CR52","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0694-180","volume":"7","author":"E Corder","year":"1994","unstructured":"Corder E, Saunders AM, Risch N, Strittmatter W, Schmechel D, Gaskell P, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180\u20134.","journal-title":"Nat Genet"},{"key":"1518_CR53","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/ana.24369","volume":"77","author":"A Serrano-Pozo","year":"2015","unstructured":"Serrano-Pozo A, Qian J, Monsell SE, Betensky RA, Hyman BT. APOE\u03b52 is associated with milder clinical and pathological Alzheimer disease. Ann Neurol. 2015;77:917\u201329.","journal-title":"Ann Neurol"},{"key":"1518_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, et al. Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11:667.","journal-title":"Nat Commun"},{"key":"1518_CR55","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nn.2858","volume":"14","author":"T Saito","year":"2011","unstructured":"Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, et al. Potent amyloidogenicity and pathogenicity of A\u03b243. Nat Neurosci. 2011;14:1023\u201332.","journal-title":"Nat Neurosci"},{"key":"1518_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/embr.201947996","volume":"21","author":"J Trambauer","year":"2020","unstructured":"Trambauer J, Rodr\u00edguez Sarmiento RM, Fukumori A, Feederle R, Baumann K, Steiner H. A\u03b243\u2010producing PS 1 FAD mutants cause altered substrate interactions and respond to \u03b3\u2010secretase modulation. EMBO Rep. 2020;21:1\u201313.","journal-title":"EMBO Rep"},{"key":"1518_CR57","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1212\/WNL.55.10.1577","volume":"55","author":"G Raux","year":"2000","unstructured":"Raux G, Gantier R, Thomas-Anterion C, Boulliat J, Verpillat P, Hannequin D, et al. Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation. Neurology.2000;55:1577\u20139.","journal-title":"Neurology"},{"key":"1518_CR58","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1136\/jnnp.57.4.416","volume":"57","author":"The Lund and Manchester Groups.","year":"1994","unstructured":"The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry. 1994;57:416\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1518_CR59","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","volume":"51","author":"D Neary","year":"1998","unstructured":"Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology.1998;51:1546\u201354.","journal-title":"Neurology"},{"key":"1518_CR60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1474-4422(09)70332-1","volume":"9","author":"BA Bergmans","year":"2010","unstructured":"Bergmans BA, De Strooper B. \u03b3-secretases: from cell biology to therapeutic strategies. Lancet Neurol. 2010;9:215\u201326.","journal-title":"Lancet Neurol"},{"key":"1518_CR61","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.neurobiolaging.2008.01.005","volume":"30","author":"L Bernardi","year":"2009","unstructured":"Bernardi L, Tomaino C, Anfossi M, Gallo M, Geracitano S, Costanzo A, et al. Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia. Neurobiol Aging. 2009;30:1825\u201333.","journal-title":"Neurobiol Aging"},{"key":"1518_CR62","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1038\/s41380-018-0224-0","volume":"25","author":"C Koriath","year":"2020","unstructured":"Koriath C, Kenny J, Adamson G, Druyeh R, Taylor W, Beck J, et al. Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series. Mol Psychiatry. 2020;25:3399\u2013412.","journal-title":"Mol Psychiatry"},{"key":"1518_CR63","doi-asserted-by":"publisher","first-page":"e1002270","DOI":"10.1371\/journal.pmed.1002270","volume":"14","author":"HM Lanoisel\u00e9e","year":"2017","unstructured":"Lanoisel\u00e9e HM, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S, et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLoS Med. 2017;14:e1002270.","journal-title":"PLoS Med"},{"key":"1518_CR64","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/35017105","volume":"2","author":"A Herreman","year":"2000","unstructured":"Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B. Total inactivation of \u03b3-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol. 2000;2:461\u20132.","journal-title":"Nat Cell Biol"},{"key":"1518_CR65","first-page":"253","volume":"83","author":"DC Ryman","year":"2014","unstructured":"Ryman DC, Aisen PS, Bird T, Danek A, Fox NC, Goate A, et al. Symptom onset in autosomal dominant Alzheimer disease a systematic review and meta-analysis. J Neurol. 2014;83:253\u201360.","journal-title":"J Neurol"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01518-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01518-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01518-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T13:03:37Z","timestamp":1668258217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01518-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1518"],"URL":"https:\/\/doi.org\/10.1038\/s41380-022-01518-6","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"20 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DP, SGF, KMZ, TE, NSR, AO\u2019C, MS, EH, RV and LCG declare no competing interests. NCF reports consultancy for Roche, Biogen and Ionis and serving on a Data Safety Monitoring Board for Biogen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}